Provenance Record

Clean, well-structured News piece (647 words, within the 400-1200 News range). Overview/What We Know/What We Don't Know structure is appropriate. Technical detail (non-viral ex vivo CRISPR/Cas9 editing at the BCL11A erythroid-specific enhancer producing fetal hemoglobin) is accurate and lifted faithfully from the Vertex release. Every specific is attributed inline.

All three source snapshots read from disk (gzipped HTML) and verified. source-0.html.gz (BioSpace/Vertex press release, HTTP 200): CONFIRMED the 'ages 2 years and older' indication for SCD with recurrent VOCs or TDT, 'first approved genetic therapy indicated for children as young as 2 years for both SCD and TDT', 'Approximately 5,500 additional children in the U.S. are now eligible', the BCL11A/erythroid-specific-enhancer/fetal-hemoglobin mechanism description, the Kewalramani and Frangoul quotes (both verbatim), and the pending Kingdom of Saudi Arabia and United Kingdom label-expansion reviews. source-1.html.gz (BioSpace-hosted FDA release distributed via GLOBE NEWSWIRE, Silver Spring MD, July 01 2026, HTTP 200): CONFIRMED all FDA-attributed specifics — July 1 2026 supplemental approval, 11-patient SCD trial with all 8 efficacy-evaluable achieving VF12 (no protocol-defined severe VOCs for 12 consecutive months within the first 24 months / two years), 15-patient TDT trial with 8 of 9 evaluable achieving transfusion independence for 12 consecutive months at a median 20.1 months, decision '53 days after filing', and the Karim Mikhail (CBER Acting Director) and Megha Kaushal (Acting Deputy Director, Office of Therapeutic Products in CBER, pediatric hematologist) quotes, both verbatim. The direct fda.gov URL had 404'd, but this BioSpace-hosted copy of the FDA's own GLOBE NEWSWIRE release fully supports every FDA-attributed figure and quote. source-2.html.gz (Healio, HTTP 200): CONFIRMED prior approval at 12 years and older, 'first and only gene therapy available for use in patients as young as 2 years', the 15-patient TDT / 9 evaluable / 8 transfusion-independent / 20.1-month median figures, and Frangoul as trial investigator. All three domains (biospace.com, healio.com) are on the source allowlist.

No hallucinations or misattributions detected. All four direct quotes appear verbatim in their cited snapshots (curly-apostrophe variants account for the only literal string differences). Enrollment counts (11 SCD / 15 TDT), evaluable counts (8 / 9), efficacy outcomes, the 20.1-month median, the 53-day timeline, and the ~5,500 eligibility figure all trace to the cited source. The 'first two years after treatment' phrasing correctly renders the source's 'within the first 24 months after infusion'.

High-quality, fully sourced News submission. Every specific, quote, enrollment count, and the FDA-attributed data (verified against the BioSpace-hosted FDA release after the direct fda.gov URL 404'd) checks out against the on-disk snapshots. Approved for publication with no corrections.